KEDRAB® (Rabies Immune Globulin [Human]) Now Shipping
May 09, 2018 |
CORPORATE
Distribution Timed to Meet Spring/Summer Demand
Human Rabies – An Interview with Peter J. Costa MPH
Mar 26, 2018 |
Rabies Immune Globulin Brand Director at Kedrion Biopharma
Global Maternal Health Milestone Reached: 50th Anniversary
Feb 12, 2018 |
CORPORATE
U.S. Approval of RhoGAM®, Rho(D) Immune Globulin
KEDRAB™: Pivotal Phase 2/3 Data presented at RITA Conference
Dec 13, 2017 |
EVENTS
Kedrion Biopharma and Kamada Received FDA Approval of the Product in Q3 2017
Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™
Aug 24, 2017 |
CORPORATE
For Post-Exposure Prophylaxis Against Rabies Infection
Kedrion Biopharma volunteers at City Rescue Mission in Jacksonville, FL
Feb 27, 2017 |
CORPORATE
US Sales & Marketing Team joined a CSR event engaging with students from CRM’s LifeBuilder program
BIVIGAM® will no longer be available for sale or distribution in 2017
Jan 23, 2017 |
CORPORATE
Distribution agreement between Biotest and Kedrion Biopharma has been terminated
KEDPLASMA Advances Long-Range Growth Plan
Jan 17, 2017 |
CORPORATE
KEDPLASMA acquires 2 FDA-licensed and EU-certified plasma collection centers from IMMUNOTEK
Kedrion Biopharma attends ASHP 2016 midyear clinical meeting
Dec 18, 2016 |
EVENTS
Kedrion Biopharma has recognized the changing role of pharmacists in the decision-making process
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment
Nov 07, 2016 |
CORPORATE
FDA has accepted for review a BLA for a human anti-rabies immunoglobulin (IgG) therapy